Combination antifungal therapy for the treatment of invasive yeast and mold infections

Current Infectious Disease Reports

Volumn 9, Issue 6, 2007, Pages 448-456

  Baddley, John W ^b   Pappas, Peter G ^a  

^a University of Alabama at Birmingham   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; EFUNGUMAB; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MONOCLONAL ANTIBODY; PLACEBO; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYPTOCOCCOSIS; DRUG ANTAGONISM; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; MONOTHERAPY; MORBIDITY; MORTALITY; MOULD; MYCOSIS; NEPHROTOXICITY; NONHUMAN; REVIEW; YEAST;

EID: 36049051251     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-007-0069-1     Document Type: Review

References (59)

1. Codish SD, Tobias JS, Hannigan M: Combined amphotericin B-flucytosine therapy in aspergillus pneumonia. JAMA 1979, 241:2418-2419.
2. Bennett JE, Dismukes WE, Duma RJ, et al.: A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979, 301:126-131.
3. Dismukes WE, Cloud G, Gallis HA, et al.: Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987, 317:334-341.
4. van der Horst C, Saag MS, Cloud GA, et al.: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997, 337:15-21.
5. Lewis RE, Klepser ME, Pfaller MA: Combination systemic antifungal therapy for cryptococcosis, candidiasis, and aspergillosis. J Infect Dis Pharmacother 1999, 3:61-84.
6. Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al.: Combination antifungal therapy. Antimicrob Agents Chemother 2004, 48:693-715.
7. Baddley JW, Pappas PG: Combination antifungal therapy: clinical potential. Drugs 2005, 65:1461-1480.
8. Lewis RE, Kontoyiannis DP: Rationale for combination antifungal therapy. Pharmacotherapy 2001, 21(8 pt 2):149S-164S.
9. Fridkin SK: The changing face of fungal infections in health care settings. Clin Infect Dis 2005, 41:1455-1460.
10. Lewis RE, Diekema DJ, Messer SA, et al.: Comparison of Etest, checquerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother 2002, 49:345-351.
11. Ghannoum MA, Fu AY, Ibrahim AS, et al.: In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob Agents Chemother 1995, 39:2459-2465.
12. Keele DJ, DeLallo VC, Lewis RE, et al.: Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology. Diagn Microbiol Infect Dis 2001, 14:121-126.
13. Polak A: Synergism of polyene antibiotics with 5-fluorocytosine. Chemotherapy 1978, 24:2-16.
14. Odds FC: Interactions among amphotericin B, 5-flurocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother 1982, 22:763-770.
15. Brajtburg J, Kobayashi D, Medoff G, et al.: Antifungal action of amphotericin B in combination with other polyene or imidazole antibiotics. J Infect Dis 1982, 146:138-146.
16. Roling E, Klepser ME, Wasson A, et al.: Antifungal activities of fluconazole and caspofungin (MK0991), and anidulafungin (LY303366) alone and in combination against Candida spp. and Cryptococcus neoformans. Diagn Microbiol Infect Dis 2002, 43:13-17.
17. Thaler M, Bacher J, O'Leary T, et al.: Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia. J Infect Dis 1988, 158:80-88.
18. Sugar AM, Hitchcock CA, Troke PF, et al.: Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother 1995, 39:598-601.
19. Marine M, Serena C, Pastor FJ, et al.: Combined antifungal therapy in a murine infection by Candida. J Antimicrob Chemother 2006, 58:1295-1298.
20. Pappas PG, Rex JH, Sobel JD, et al.: Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38:161-189.
21. Abele-Horn M, Kopp A, Sternberg U, et al.: A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996, 24:426-432.
22. Rex JH, Pappas PG, Karchmer AW, et al.: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003, 36:1221-1228.
23. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al.: International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005, 24:662-664.
24. Matthews RC, Rigg G, Hodgetts S, et al.: Preclinical assessment of the clinical efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother. 2003, 47:2208-2216.
25. Pachl J, Svoboda P, Jacobs F, et al.: A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006, 42:1404-1413.
26. Barchiesi F, Gallo D, Caselli F, et al.: In vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. J Antimicrob Chemother 1999, 44:65-70.
27. Barchiesi F, Schimizzi AM, Caselli F, et al.: Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother 2000, 44:2435-2441.
28. Graybill JR, Williams M, Van Cutsem E, et al.: Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole. Rev Infect Dis 1980, 2:551-558.
29. Franzot SP, Casadevall A: Pneumocandin L-743, 872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother 1997, 41:331-336.
30. Bava AJ, Negroni R: Comparative study of six antifungal treatments in an experimental model of murine cryptococcosis. Eur J Epidemiol 1992, 8:422-426.
31. Polak, A, Scholer HJ, Wall M: Combination therapy of experimental candidiasis, cryptococcosis, and aspergillosis in mice. Chemotherapy 1982, 28:461-479.
32. Ding JC, Bauer M, Diamond DM, et al.: Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob Agents Chemother 1997, 41:1589-1593.
33. Larsen RA, Bauer M, Thomas AM, et al.: Amphotericin B combined with fluconazole is better than all other combinations for cryptococcal meningitis [abstract 17]. Presented at the Focus on Fungal Infections 12 Meeting. Phoenix, AR; March 20-22, 2002.
34. Saag MS, Graybill RJ, Larsen RA, et al.: Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000, 30:710-718.
35. Larsen RA, Leal ME, Chan LS: Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990, 113:183-187.
36. Saag MS, Powderly WG, Cloud GA, et al.: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992, 326:83-89.
37. Saag MS, Cloud GA, Graybill JR, et al.: A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999, 28:291-296.
38. Larsen RA, Bozzette SA, Jones BE, et al.: Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994, 19:741-745.
39. Brouwer AE, Rajanuwong A, Chierakul W, et al.: Combination therapies for HIV associated cryptococcal meningitis: a randomized trial. Lancet 2004, 363:1764-1767.
40. Pappas PG, Larsen RA, Chenkostad P, et al.: Combination amphotericin B plus fluconazole versus amphotericin B alone for treatment of acute cryptococcal meningitis [abstract]. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 17-20, 2007.
41. Herbrecht R, Denning DW, Patterson TF, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New Engl J Med 2002, 347:408-415.
42. Walsh TJ, Raad I, Patterson TG, et al.: Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007, 44:2-12.
43. Maertens J, Raad I, Petrikkos G, et al.: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients reftactory to on intolerant of conventional antifungal therapy. Clin Infect Dis 2004, 39:1563-1571.
44. Denning DW, Marr Ka, Lau WM, et al.: Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006, 53:337-349.
45. Denning DW, Hanson LA, Perlman AM, et al.: In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 1992, 15:21-34.
46. Meletiadis J, Petraitis V, Petratiene R, et al.: Triazole-polyene antagonism in experimental pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 2006, 194:1008-1018.
47. Arikan S, Lozano-Chiu M, Paetznik V, et al.: In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002, 46:245-247.
48. Perea SG, Gonzalez G, Fothergill AW, et al.: In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002, 46:3039-3041.
49. Polak A: Combination therapy with antifungal drugs. Mycoses 1988, 31(Suppl 2):45S-53S.
50. Clemons KV, Espiritu M, Parmar R, et al.: Comparative efficacies of conventional amphotericin b, liposomal amphotericin b (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against murine cental nervous system aspergillosis. Antimicrob Agents Chemother 2005, 49:4867-4875.
51. Petraitis V, Petraitiene R, Sarafandi AA, et al.: Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. Journal Infect Dis 2003, 187:1834-1843.
52. Kirkpatrick WR, Perea S, Coco BJ, et al.: Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002, 46:2564-2568.
53. Petraitis V, Petraitiene R, Legit RJ, et al.: Combination antifungal therapy with FK463 plus amphotericin B in treatment of experimental pulmonary aspergillosis [abstract 2003]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco; September 26-29, 1999.
54. Stevens DA, Kan VL, Judson MA, et al.: Practice guidelines for disease caused by Aspergillus. Clin Infect Dis 2000, 30:696-709.
55. Aliff TB, Maslak PG, Jurcic JG, et al.: Refractory aspergillus pneumonia in patients with acute leukemia. Cancer 2003, 97:1025-1032.
56. Kontoyiannis DP, Hachen R, Lewis RE, et al.: Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003, 98:292-299.
57. Marr KA, Boeckth M, Carter RA, et al.: Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797-802.
58. Singh N, Limaye AP, Forrest G, et al.: Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006, 81:320-326.
59. Steinbach WJ, Stevens DA, Denning DW: Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2002, 37(Suppl 3):188S-224S.